pyrazines has been researched along with pyrogallol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esberg, LB; Ren, J | 1 |
| Coelho-Silva, JL; Fenerich, BA; Fernandes, JC; Machado-Neto, JA; Rego, EM; Ridley, AJ; Rodrigues Alves, APN; Scheucher, PS; Simões, BP; Traina, F | 1 |
2 other study(ies) available for pyrazines and pyrogallol
| Article | Year |
|---|---|
The oxygen radical generator pyrogallol impairs cardiomyocyte contractile function via a superoxide and p38 MAP kinase-dependent pathway: protection by anisodamine and tetramethylpyrazine.
Topics: Animals; Dose-Response Relationship, Drug; Drug Antagonism; Drugs, Chinese Herbal; Enzyme Inhibitors; Free Radical Scavengers; Imidazoles; Male; Myocardial Contraction; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Pyrazines; Pyridines; Pyrogallol; Rats; Rats, Sprague-Dawley; Solanaceous Alkaloids; Superoxide Dismutase; Superoxides | 2004 |
IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Jurkat Cells; Middle Aged; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrogallol; Receptor, IGF Type 1; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Young Adult | 2019 |